Přejít k obsahu
Merck

124011

Akt Inhibitor IV

≥98% (HPLC), solid

Synonyma:

Akt Inhibitor IV

Přihlásit pro zobrazení organizačních a smluvních cen.

Vybrat velikost

1 MG

4 270,00 Kč

5 MG

15 400,00 Kč

4 270,00 Kč


K dispozici k odeslání DNESpodrobné informace



O této položce

Empirický vzorec (Hillův zápis):
C31H27IN4S
Číslo CAS:
Molekulová hmotnost:
614.54
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:

Přeskočit na

Technický servis
Potřebujete pomoc? Náš tým zkušených odborníků je vám k dispozici.
Dovolte nám, abychom vám pomohli

Název produktu

Akt Inhibitor IV, The Akt Inhibitor IV, also referenced under CAS 681281-88-9, controls the biological activity of Akt. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

SMILES string

[I-].[s]1c2c(nc1c3cc4[n](c([n+](c4cc3)c6ccccc6)C=CN(C)c5ccccc5)CC)cccc2

InChI

1S/C31H27N4S.HI/c1-3-34-28-22-23(31-32-26-16-10-11-17-29(26)36-31)18-19-27(28)35(25-14-8-5-9-15-25)30(34)20-21-33(2)24-12-6-4-7-13-24;/h4-22H,3H2,1-2H3;1H/q+1;/p-1

InChI key

NAYRELMNTQSBIN-UHFFFAOYSA-M

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated (hygroscopic)
protect from light

color

yellow

solubility

DMSO: 5 mg/mL

shipped in

ambient

storage temp.

2-8°C

Quality Level

Porovnat podobné položky

Zobrazit úplné porovnání

Zobrazit rozdíly

1 of 4

Tato položka
124015124018124008
form

solid

form

liquid

form

solid

form

solid

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥95% (HPLC)

assay

≥98% (NMR)

Quality Level

100

Quality Level

100

Quality Level

200

Quality Level

100

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

solubility

DMSO: 5 mg/mL

solubility

-

solubility

DMSO: 5 mg/mL

solubility

DMSO: 10 mg/mL

Biochem/physiol Actions

Cell permeable: yes
Primary Target
Akt
Product does not compete with ATP.
Reversible: yes
Target IC50: 625 nM in blocking Akt-mediated FOXO1a nuclear export; <1.25 µM in blocking Akt-mediated cell proliferation in 786-O cells

Disclaimer

Toxicity: Standard Handling (A)

General description

A cell permeable and reversible benzimidazole compound that inhibits Akt phosphorylation/activation by targeting the ATP binding site of a kinase upstream of Akt, but downstream of PI 3-K. Shown to block Akt-mediated FOXO1a nuclear export (IC50 = 625 nM) and cell proliferation (IC50<1.25 M) in 786-O cells. Unlike phosphatidylinositol analog-based Akt inhibitors (Cat. Nos. 124005, 124008, 124009), this inhibitor does not affect PI3K. A 10 mM (1 mg/163 l) solution of Akt Inhibitor IV in DMSO is also available.
A cell-permeable and reversible benzimidazole compound that inhibits Akt phosphorylation/activation presumably by targeting the ATP binding site of a kinase upstream of Akt, but downstream of PI3-K. Shown to block Akt-mediated FOXO1a nuclear export (IC50 = 625 nM) and cell proliferation (IC50<1.25 µM) in 786-O cells. Unlike phosphatidylinositol analog-based Akt inhibitors (Cat. Nos. 124005, 124008, 124009), this inhibitor does not affect PI3-K.

Other Notes

Kau, T.R., et al. 2003. Cancer Cell4, 463.



Selected Citations
Lee, J., et al. 2009. Cell Stem Cell5, 76.


Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Skladovací třída

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Mengping Zhang et al.
Journal of cellular physiology, 233(6), 4748-4758 (2017-11-18)
While overexpression of FSCN1 is reported in several cancers, the prognostic significance of FSCN1 in renal cell carcinoma (RCC) and the molecular mechanisms involved remain largely unclear. We retrospectively enrolled 194 patients with non-metastatic clear-cell RCC undergoing nephrectomy in our
Oleksii S Rukhlenko et al.
Nature, 609(7929), 975-985 (2022-09-15)
Understanding cell state transitions and purposefully controlling them is a longstanding challenge in biology. Here we present cell state transition assessment and regulation (cSTAR), an approach for mapping cell states, modelling transitions between them and predicting targeted interventions to convert
Bing Xu et al.
Frontiers in neuroscience, 14, 766-766 (2020-08-28)
Poor postoperative pain (POP) control increases perioperative morbidity, prolongs hospitalization days, and causes chronic pain. However, the specific mechanism(s) underlying POP is unclear and the identification of optimal perioperative treatment remains elusive. Akt and mammalian target of rapamycin (mTOR) are
Michael Xiao et al.
eLife, 12 (2023-04-14)
Quiescent stem cells are activated in response to a mechanical or chemical injury to their tissue niche. Activated cells rapidly generate a heterogeneous progenitor population that regenerates the damaged tissues. While the transcriptional cadence that generates heterogeneity is known, the
Roshini Fernando et al.
Journal of immunology (Baltimore, Md. : 1950), 204(7), 1724-1735 (2020-02-23)
IL-23 and IL-12, two structurally related heterodimeric cytokines sharing a common subunit, divergently promote Th cell development and expansion. Both cytokines have been implicated in the pathogenesis of thyroid-associated ophthalmopathy (TAO), an autoimmune component of Graves disease. In TAO, CD34+

Sortimentní položky

AldeRed™ 588-A detects ALDH activity in cancer stem cells, aiding in cancer research.

Související obsah

Human Kinome Poster: The InhibitorSelect™ Protein Kinase Inhibitor Libraries provide broad coverage of the human kinome as shown here. The depicted human kinome dendrogram of 518 kinases are classified into five broad groups, 90 families, and 145 subfamilies. Inhibitor coverage was assigned based upon published data related to potency (IC50, EC50, Kd, etc.) for individual kinases harvested from the literature. Colored dots denote which library contains an inhibitor with demonstrated potent activity against the designated kinase and do not necessarily reflect known specificity of the inhibitor. Coverage of lipid and atypical kinases are depicted as a separate dendrogram. As shown, Calbiochem® Protein Kinase Inhibitor Libraries cover all major kinase families including TK, CMGC, CAMK, AGC, CK1, STE, TKL, as well as Lipid or Atypical kinase families.

Questions

Reviews

No rating value

Active Filters

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis